

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation and Petition to Revoke
Probation Against:

Case No. 5547

OAH No. 2016060840

**MEDICAL DENTAL PHARMACY, INC.,
dba MEDICAL DENTAL PHARMACY
DIANA LYNN SMITH,
aka DIANA SMITH,
aka DIANA MORTON,
aka DIANA LYNN MORTON, CEO/PIC
CAROLYN SMITH,
aka CAROLYN ELIZABETH SMITH,
TREAS/CFO
Pharmacy Permit No. PHY 44342**

**DIANA LYNN SMITH
Pharmacist License No. RPH 45423**

and

**DAREK TERRELL JONES
Pharmacist License No. RPH 59702**

Respondents.


DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on February 10, 2017.

It is so ORDERED on January 11, 2017.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA



By

Amy Gutierrez, Pharm.D.
Board President

1 KAMALA D. HARRIS
Attorney General of California
2 JANICE K. LACHMAN
Supervising Deputy Attorney General
3 KRISTINA T. JARVIS
Deputy Attorney General
4 State Bar No. 258229
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 324-5403
Facsimile: (916) 327-8643
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
DEPARTMENT OF CONSUMER AFFAIRS
10 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation and Petition to
12 Revoke Probation Against:

13 **MEDICAL DENTAL PHARMACY, INC.,**
14 **dba MEDICAL DENTAL PHARMACY**
DIANA LYNN SMITH,
15 **aka DIANA SMITH**
aka DIANA MORTON,
16 **aka DIANA LYNN MORTON, CEO/PIC**
CAROLYN SMITH,
17 **aka CAROLYN ELIZABETH SMITH,**
TREAS/CFO
18 **689 E. Nees**
Fresno, CA 93720

19 **Pharmacy Permit No. PHY 44342,**
20 **and**

21 **DIANA LYNN SMITH**
22 **aka DIANA LYNN MORTON**
9798 N. Sunnyside Avenue
Clovis, CA 93619

23 **Pharmacist License No. RPH 45423,**

24 **and**

25 **DAREK TERRELL JONES**
26 **1218 E. Champlain Drive, #208**
Fresno, CA 93729

27 **Pharmacist License No. RPH 59702**

28 **Respondents.**

Case No. 5547

OAH No. 2016060840

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER FOR PUBLIC
REPROVAL

(RESPONDENT DAREK JONES ONLY)

[Bus. & Prof. Code § 495]

1 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
2 entitled proceedings that the following matters are true:

3 **PARTIES**

4 1. Virginia Herold (Complainant) is the Executive Officer of the Board of Pharmacy
5 (Board). She brought this action solely in her official capacity and is represented in this matter by
6 Kamala D. Harris, Attorney General of the State of California, by Kristina T. Jarvis, Deputy
7 Attorney General.

8 2. On or about August 13, 1999, the Board issued Pharmacy Permit Number PHY
9 44342 to Medical Dental Pharmacy, Inc. ("Respondent MDP"), doing business as Medical Dental
10 Pharmacy, with Carolyn Smith, also known as Carolyn Elizabeth Smith, as chief financial officer
11 and treasurer and Diana Lynn Smith, also known as (aka) Diana Lynn Morton, aka Diana Morton,
12 aka Diana Smith ("Respondent Smith"), as secretary. On or about September 1, 2005,
13 Respondent Smith became the pharmacist-in-charge. On or about January 25, 2010, Respondent
14 Smith became the chief executive officer. The pharmacy permit was in full force and effect at all
15 times relevant to the charges brought herein and will expire on August 1, 2017, unless renewed.

16 3. On or about August 12, 1992, the Board issued Pharmacist License Number RPH
17 45423 to Respondent Smith. The pharmacist license was in full force and effect at all times
18 relevant to the charges brought herein and will expire on May 31, 2018, unless renewed.

19 4. On or about July 3, 2007, the Board issued Pharmacist License Number RPH 59702
20 to Darek Terrell Jones ("Respondent Jones"). The pharmacist license was in effect at all times
21 relevant to the charges brought herein and will expire on January 31, 2017, unless renewed.

22 5. In a disciplinary action entitled "In the Matter of the Accusation Against: Darek
23 Terrell Jones," Case No. 3813, the Board issued a Decision and Order effective May 18, 2012, in
24 which Respondent Jones' pharmacist license was revoked. However, the revocation was stayed
25 and Respondent's pharmacist license was placed on probation for five (5) years with certain terms
26 and conditions. Respondent was also suspended from the practice of pharmacy for ninety (90)
27 days beginning on the effective date of the Decision.

28 ///

6. Respondents MDP and Smith are represented by attorney Ivan Petzelka, California Pharmacy Lawyers, whose address is 2855 Michelle Drive, Suite 180, Irvine, California 92606-1027.

7. Respondent Jones is represented by attorney Paul Chan, Law Offices of Paul Chan, whose address is 2311 Capitol Avenue, Sacramento, California 95816.

JURISDICTION

8. Accusation No. 5547 was filed before the Board of Pharmacy (Board), Department of Consumer Affairs and is currently pending against Respondent Jones. The Accusation and all other statutorily required documents were properly served on Respondent Jones on April 7, 2016. Respondent Jones timely filed his Notice of Defense contesting the Accusation. A copy of Accusation No. 5547 is attached as exhibit A and incorporated herein by reference.

ADVISEMENT AND WAIVERS

9. Respondent Jones has carefully read, fully discussed with counsel, and understands the charges and allegations in Accusation No. 5547. Respondent Jones has also carefully read, fully discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary Order for Public Reprimand.

10. Respondent Jones is fully aware of his legal rights in this matter, including the right to a hearing on the charges and allegations in the Accusation; the right to be represented by counsel at his own expense; the right to confront and cross-examine the witnesses against him; the right to present evidence and to testify on his own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.

11. Respondent Jones voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

///

///

///

1 **CULPABILITY**

2 12. Respondent Jones admits the truth of each and every charge and allegation with
3 which he is charged in Accusation No. 5547.

4 13. Respondent Jones agrees that his Pharmacist License is subject to discipline and
5 agrees to be bound by the Disciplinary Order below.

6 **CONTINGENCY**

7 14. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent
8 Jones understands and agrees that counsel for Complainant and the staff of the Board of
9 Pharmacy may communicate directly with the Board regarding this stipulation and settlement,
10 without notice to or participation by Respondent Jones or his counsel. By signing the stipulation,
11 Respondent Jones understands and agrees that he may not withdraw his agreement or seek to
12 rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to
13 adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order
14 for Public Repeval shall be of no force or effect, except for this paragraph, it shall be
15 inadmissible in any legal action between the parties, and the Board shall not be disqualified from
16 further action by having considered this matter.

17 15. The parties understand and agree that Portable Document Format (PDF) and facsimile
18 copies of this Stipulated Settlement and Disciplinary Order for Public Repeval, including PDF
19 and facsimile signatures thereto, shall have the same force and effect as the originals.

20 16. This Stipulated Settlement and Disciplinary Order for Public Repeval is intended by
21 the parties to be an integrated writing representing the complete, final, and exclusive embodiment
22 of their agreement. It supersedes any and all prior or contemporaneous agreements,
23 understandings, discussions, negotiations, and commitments (written or oral). This Stipulated
24 Settlement and Disciplinary Order for Public Repeval may not be altered, amended, modified,
25 supplemented, or otherwise changed except by a writing executed by an authorized representative
26 of each of the parties.

27 ///

28 ///

1 17. In consideration of the foregoing admissions and stipulations, the parties agree that
2 the Board may, without further notice or formal proceeding, issue and enter the following
3 Disciplinary Order:

4 **DISCIPLINARY ORDER**

5 IT IS HEREBY ORDERED that Pharmacist License Number RPH 59702 issued to
6 Respondent Darek Jones shall be publicly reprovved by the Board of Pharmacy under Business
7 and Professions Code section 495 in resolution of Accusation No. 5547, attached as exhibit A.

8 **ACCEPTANCE**

9 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
10 Reproval and have fully discussed it with my attorney, Paul Chan. I understand the stipulation
11 and the effect it will have on my Pharmacist License. I enter into this Stipulated Settlement and
12 Disciplinary Order for Public Reproval voluntarily, knowingly, and intelligently, and agree to be
13 bound by the Decision and Order of the Board of Pharmacy.

14
15 DATED: 11/29/16


16 DAREK JONES
17 Respondent

18 **APPROVAL AS TO FORM AND CONTENT**

19 I have read and fully discussed with Respondent Darek Jones the terms and conditions and
20 other matters contained in the above Stipulated Settlement and Disciplinary Order for Public
21 Reproval. I approve its form and content.

22
23 DATED: 11/30/16


24 PAUL CHAN
25 Attorney for Respondent

26 ///

27 ///

28 ///


ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order for Public Reapproval is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

Dated: November 30, 2016

Respectfully submitted,

KAMALA D. HARRIS
Attorney General of California
JANICE K. LACHMAN
Supervising Deputy Attorney General


KRISTINA T. JARVIS
Deputy Attorney General
Attorneys for Complainant

SA2015104552
12510646.doc

Exhibit A

Accusation No. 5547

1 KAMALA D. HARRIS
Attorney General of California
2 JANICE K. LACHMAN
Supervising Deputy Attorney General
3 KRISTINA T. JARVIS
Deputy Attorney General
4 State Bar No. 258229
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 324-5403
Facsimile: (916) 327-8643
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Accusation and Petition to
12 Revoke Probation Against:

Case No. 5547

13 **MEDICAL DENTAL PHARMACY, INC.,**
14 **dba MEDICAL DENTAL PHARMACY**
15 **DIANA LYNN SMITH,**
16 **aka DIANA SMITH**
17 **aka DIANA MORTON,**
18 **aka DIANA LYNN MORTON, CEO/PIC**
19 **CAROLYN SMITH,**
20 **aka CAROLYN ELIZABETH SMITH,**
21 **TREAS/CFO**
22 **689 E. Nees**
23 **Fresno, CA 93720**

ACCUSATION AND PETITION TO
REVOKE PROBATION

(Petition as to Respondent Darek Terrell
Jones only)

24 **Pharmacy Permit No. PHY 44342,**

25 **DIANA LYNN SMITH**
26 **aka DIANA LYNN MORTON,**
27 **9798 N. Sunnyside Avenue**
28 **Clovis, CA 93619**

Pharmacist License No. RPH 45423,

and

29 **DAREK TERRELL JONES**
30 **1218 E. Champlain Drive, #208**
31 **Fresno, CA 93729**

Pharmacist License No. RPH 59702

Respondents.

1 Complainant alleges:

2 **PARTIES**

3 1. Virginia Herold ("Complainant") brings this Accusation and Petition to Revoke
4 Probation solely in her official capacity as the Executive Officer of the Board of Pharmacy
5 ("Board"), Department of Consumer Affairs.

6 2. On or about August 13, 1999, the Board issued Pharmacy Permit Number PHY
7 44342 to Medical Dental Pharmacy, Inc. ("Respondent MDP"), doing business as Medical Dental
8 Pharmacy, with Carolyn Smith, also known as Carolyn Elizabeth Smith, as chief financial officer
9 and treasurer and Diana Lynn Smith, also known as (aka) Diana Lynn Morton, aka Diana Morton,
10 aka Diana Smith ("Respondent Smith"), as secretary. On or about September 1, 2005,
11 Respondent Smith became the pharmacist-in-charge. On or about January 25, 2010, Respondent
12 Smith became the chief executive officer. The pharmacy permit was in full force and effect at all
13 times relevant to the charges brought herein and will expire on August 1, 2016, unless renewed.

14 3. On or about August 12, 1992, the Board issued Pharmacist License Number RPH
15 45423 to Respondent Smith. The pharmacist license was in full force and effect at all times
16 relevant to the charges brought herein and will expire on May 31, 2016, unless renewed.

17 4. On or about July 3, 2007, the Board issued Pharmacist License Number RPH 59702
18 to Darek Terrell Jones ("Respondent Jones"). The pharmacist license was in effect at all times
19 relevant to the charges brought herein and will expire on January 31, 2017, unless renewed.

20 5. In a disciplinary action entitled "In the Matter of the Accusation Against: Darek
21 Terrell Jones," Case No. 3813, the Board issued a Decision and Order effective May 18, 2012, in
22 which Respondent Jones' pharmacist license was revoked. However, the revocation was stayed
23 and Respondent's pharmacist license was placed on probation for five (5) years with certain terms
24 and conditions. Respondent was also suspended from the practice of pharmacy for ninety (90)
25 days beginning on the effective date of the Decision.

26 ///

27 ///

28 ///

JURISDICTION AND STATUTORY PROVISIONS

6. This Accusation and Petition to Revoke Probation is brought before the Board under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.

7. Section 4300 states, in pertinent part:

(a) Every license issued may be suspended or revoked.

(b) The board shall discipline the holder of any license issued by the board, whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:

(1) Suspending judgment.

(2) Placing him or her upon probation.

(3) Suspending his or her right to practice for a period not exceeding one year.

(4) Revoking his or her license.

(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper . . .

8. Section 4300.1 states:

The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.

9. Section 4301 states, in pertinent part:

The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

(j) The violation of any of the statutes of this state, of any other state, or of the United States regulating controlled substances and dangerous drugs.

(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency . . .

///

10. Section 4306.5 states in pertinent part:

Unprofessional conduct for a pharmacist may include any of the following:

(a) Acts or omissions that involve, in whole or in part, the inappropriate exercise of his or her education, training, or experience as a pharmacist, whether or not the act or omission arises in the course of the practice of pharmacy or the ownership, management, administration, or operation of a pharmacy or other entity licensed by the board.

(b) Acts or omissions that involve, in whole or in part, the failure to exercise or implement his or her best professional judgment or corresponding responsibility with regard to the dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices, or with regard to the provision of services.

(c) Acts or omissions that involve, in whole or in part, the failure to consult appropriate patient, prescription, and other records pertaining to the performance of any pharmacy function.

11. Section 4113, subdivision (c), states that "[t]he pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy."

12. Section 4025 states:

"Drug" means any of the following:

(a) Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement of any of them.

(b) Articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in human beings or other animals.

(c) Articles (other than food) intended to affect the structure or any function of the body of human beings or other animals.

(d) Articles intended for use as a component of any article specified in subdivision (a), (b), or (c).

13. Section 4342, subdivision (a), states:

The board may institute any action or actions as may be provided by law and that, in its discretion, are necessary, to prevent the sale of pharmaceutical preparations and drugs that do not conform to the standard and tests as to quality and strength, provided in the latest edition of the United States Pharmacopoeia or the National Formulary, or that violate any provision of the Sherman Food, Drug, and

1 Cosmetic Law (Part 5 (commencing with Section 109875) of Division 104 of the
2 Health and Safety Code).

3 14. Health and Safety Code section 111335 provides that any drug or device is
4 misbranded if its labeling or packaging does not conform to the requirements of Chapter 4
5 (commencing with Section 110290.)

6 15. Health and Safety Code section 110290 states:

7 In determining whether the labeling or advertisement of a food, drug, device, or cosmetic is
8 misleading, all representations made or suggested by statement, word, design, device, sound, or
9 any combination of these, shall be taken into account. The extent that the labeling or advertising
10 fails to reveal facts concerning the food, drug, device, or cosmetic or consequences of customary
11 use of the food, drug, device, or cosmetic shall also be considered.

12 16. Health and Safety Code section 111330 states that [a]ny drug or device is misbranded
13 if its labeling is false or misleading in any particular.

14 17. Health and Safety Code section 111400 provides that any drug or device is
15 misbranded if it is dangerous to health when used in the dosage, or with the frequency or duration
16 prescribed, recommended, or suggested in its labeling.

17 18. Health and Safety Code section 111440 provides that it is unlawful for any person to
18 manufacture, sell, deliver, hold, or offer for sale any drug or device that is misbranded.

19 19. Health and Safety Code section 111450 provides that it is unlawful for any person to
20 receive in commerce any drug or device that is misbranded or to deliver or proffer for delivery
21 any drug or device.

22 20. Health and Safety Code section 111550 provides, in pertinent part:

23 No person shall sell, deliver, or give away any new drug or new device
24 unless it satisfies either of the following:

25 (a) It is one of the following:

26 (1) A new drug, and a new drug application has been approved for it and
27 that approval has not been withdrawn, terminated, or suspended under Section 505 of
28 the federal act (21 U.S.C. Sec. 355).

 (b) The department has approved a new drug or device application for
 that new drug or new device and that approval has not been withdrawn, terminated, or
 suspended . . .

1 21. Section 201, subdivision (p), of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
2 section 321, subdivision (p)), states, in pertinent part:

3 The term "new drug" means--

4 (1) Any drug . . . the composition of which is such that such drug is not
5 generally recognized, among experts qualified by scientific training and experience to
6 evaluate the safety and effectiveness of drugs, as safe and effective for use under the
condition prescribed, recommended, or suggested in the labeling thereof . . .

7 (2) Any drug . . . the composition of which is such that such drug, as a
8 result of investigations to determine its safety and effectiveness for use under such
9 conditions, has become so recognized, but which has not, otherwise than in such
investigations, been used to a material extent or for a material time under such
conditions.

10 22. Title 21 United States Code section 352 states in pertinent part:

11 A Drug or device shall be deemed to be misbranded—

12 (f) Directions for use and warnings on label

13 Unless its labeling bears (1) adequate directions for use; and (2) such adequate
14 warnings against use in those pathological conditions or by children where its use
15 may be dangerous to health, or against unsafe dosage or methods or duration of
16 administration or application, in such manner and form, as are necessary for the
17 protection of users, except that where any requirement of clause (1) of this paragraph,
18 as applied to any drug or device, is not necessary for the protection of the public
19 health, the Secretary shall promulgate regulations exempting such drug or device
20 from such requirement. Required labeling for prescription devices intended for use in
health care facilities or by a health care professional and required labeling for in vitro
diagnostic devices intended solely by electronic means, provided that the labeling
complies with all applicable requirements of law, and that the manufacturer affords
such users the opportunity to request the labeling in paper form, and after such
request, promptly provides the requested information without additional cost.

21 23. Section 505, subdivision (a), of the Act (21 U.S.C. section 355, subdivision (a)),
22 states, in pertinent part, that ". . . [n]o person shall introduce or deliver for introduction into
23 interstate commerce any new drug, unless an approval of an application filed pursuant to
subsection (b) or (j) is effective with respect to such drug."

24 **COST RECOVERY**

25 24. Section 125.3 provides, in pertinent part, that a Board may request the administrative
26 law judge to direct a licensee found to have committed a violation or violations of the licensing
27 act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the
28 case.

1 **DRUG**

2 25. "Domperidone" is an anti-dopaminergic drug that acts as an antiemetic and a
3 prokinetic agent. It is used relieve nausea and vomiting, and to increase lactation. It is a
4 dangerous drug under Business and Professions Code section 4022. Domperidone is not
5 currently a legally marketed human drug and is not approved for sale in the United States. The
6 FDA has determined that any products containing domperidone are unapproved new drugs and
7 misbranded. Consequently, any product containing domperidone violates the Federal Food,
8 Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.).

9 **FACTUAL ALLEGATIONS**

10 26. On or about June 7, 2004, the U.S. Food and Drug Administration ("FDA") issued a
11 Talk Paper titled, "FDA Warns Against Women Using Unapproved Drug, Domperidone, to
12 Increase Milk Production", warning breastfeeding women not to use the product because of safety
13 concerns. The FDA stated that although domperidone was approved in several countries outside
14 the U.S. to treat certain gastric disorders, it is not approved in any country, including the U.S., for
15 enhancing breast milk production in lactating women and is also not approved in the U.S. for any
16 indication.¹ The Talk Paper indicated that the FDA had issued six letters to pharmacies that
17 compound products containing domperidone and firms that supply domperidone for use in
18 compounding, stating that all drug products containing domperidone (whether compounded or
19 not) violated the Federal Food, Drug and Cosmetic Act ("the Act") because they are unapproved
20 new drugs and misbranded.

21 27. On or about June 7, 2004, the FDA issued a warning letter to Spectrum Chemicals &
22 Laboratory Products. The FDA stated that their inspection of the firm revealed they were
23 repacking and distributing bulk API (active pharmaceutical ingredient) domperidone for use in
24 pharmacy compounding in violation of the Act. The FDA also stated that the drug's labeling did
25

26 ¹ The FDA stated that there had been several published reports and case studies of cardiac
27 arrhythmias, cardiac arrest, and sudden death in patients receiving an IV form of domperidone
28 that had been withdrawn from marketing in a number of countries. Further, in several countries
where the oral form of domperidone continued to be marketed, labels for the product contained
specific warnings against use of domperidone by breastfeeding women.

1 not contain adequate directions for use and that domperidone was not an active ingredient
2 contained in any FDA-approved drug product.

3 28. On or about April 9, 2010, the FDA issued a warning letter to Alexandria Medical.
4 Arts Pharmacy & Compounding Laboratory. The FDA found during their inspection of the firm
5 that they had compounded domperidone products for human patients on numerous occasions.
6 The FDA stated that the domperidone products compounded by the firm were new drugs as
7 defined by section 201(p) [21 U.S.C. section 321(p)] of the Act and may not be introduced or
8 delivered into interstate commerce under section 505(a) of the Act [21 U.S.C. section 355(a)]
9 because no approval of an application filed pursuant to section 505 of the Act [21 U.S.C. section
10 335] is in effect for the products.

11 29. On or about March 12, 2012, the FDA issued Import Alert 61-07, stating that
12 domperidone was being imported as a bulk API for pharmacy compounding and that importation
13 of the drug presented a public health risk and violated the Act.

14 30. On or about March 20, 2015, the Board received a complaint, alleging that
15 Respondent MDP was compounding domperidone.

16 31. On or about April 21, 2015, Board Inspectors conducted a routine inspection and
17 complaint investigation of Respondent MDP's pharmacy and were assisted by Respondent Smith.
18 The inspectors requested and obtained the pharmacy's compounding record for the past year and
19 found that domperidone was being compounded for different strengths. One of the inspectors
20 also located a 500 gram bulk container of domperidone powder inside the expired medication bin.
21 The inspectors requested and obtained the pharmacy's domperidone dispensing record,
22 compounding logs, and domperidone prescriptions filled within the last year. The inspectors
23 asked Respondent Smith about the extent of domperidone compounding by the pharmacy.
24 Respondent Smith stated that she stopped all domperidone compounding and dispensing activities
25 upon receiving the domperidone alert from the Board, and placed the remaining bulk powder in
26 the expired medication bin.

27 32. On or about May 27, 2015, Respondent Smith provided additional records to the
28 Board.

1 33. Domperidone may be able to be compounded and dispensed if an Investigational New
2 Drug (IND) Application is filed with the Federal Drug Administration (FDA) and approved.
3 Respondents did not file an IND Application in order to compound or dispense domperidone.

4 34. The inspectors determined, based on the documents provided by Respondent Smith,
5 that on and between April 21, 2014 and April 21, 2015, the pharmacy had compounded 32
6 batches and 3,400 capsules of various strengths of domperidone. 30 batches and 3,200 capsules
7 had been compounded by Respondent Smith; 2 batches and 200 capsules had been compounded
8 by Respondent Jones. The pharmacy had also dispensed approximately 47 prescriptions and
9 3,552 capsules to patients which were compounded from domperidone. Respondent Smith had
10 dispensed approximately 43 of the prescriptions and approximately 3,288 of the capsules;
11 Respondent Jones had dispensed approximately 4 of the prescriptions and approximately 264 of
12 the capsules.

13 **FIRST CAUSE FOR DISCIPLINE**

14 **(Failure to Exercise or Implement Best Professional Judgment or Corresponding**
15 **Responsibility)**

16 35. Respondents Smith and Jones are subject to disciplinary action for unprofessional
17 conduct pursuant to Code section 4301, as defined by Code section 4306.5 subdivision (b), for
18 failing to exercise or implement their best professional judgment or corresponding responsibility,
19 by compounding and dispensing domperidone even though there was no IND Application
20 approved by the FDA, as set forth in paragraphs 31-34, above.

21 **SECOND CAUSE FOR DISCIPLINE**

22 **(Failing to Consult Appropriate Records)**

23 36. Respondents Smith and Jones are subject to disciplinary action for unprofessional
24 conduct pursuant to Code section 4301, as defined by Code section 4306.5 subdivision (c), for
25 failing to consult appropriate records pertaining to compounding and dispensing domperidone
26 even though there was no IND Application approved by the FDA, as set forth in paragraphs 31-
27 34, above.

28 ///

1 **THIRD CAUSE FOR DISCIPLINE**

2 **(Sold Misbranded Drugs)**

3 37. Respondents MDP, Smith, and Jones are subject to disciplinary action for
4 unprofessional conduct pursuant to Code section 4301 subdivision (j), for violating statutes
5 regulating controlled substances and dangerous drugs, in that Respondents sold misbranded
6 drugs, as defined by Health & Safety Code sections 110290, 111330, and United States Code,
7 title 21, section 352(f), in violation of Health and Safety Code section 111440, as set forth in
8 paragraphs 31 through 34, above.

9 **FOURTH CAUSE FOR DISCIPLINE**

10 **(Delivered or Proffered for Delivery Misbranded Drugs)**

11 38. Respondents MDP, Smith, and Jones are subject to disciplinary action for
12 unprofessional conduct pursuant to Code section 4301 subdivision (j), for violating statutes
13 regulating controlled substances and dangerous drugs, in that Respondents delivered or proffered
14 for delivery misbranded drugs, as defined by Health & Safety Code sections 110290, 111330, and
15 111400, in violation of Health and Safety Code section 111450, as set forth in paragraphs 31
16 through 34, above.

17 **FIFTH CAUSE FOR DISCIPLINE**

18 **(Violations of the Pharmacy Law and**

19 **Federal and State Laws Governing Pharmacy)**

20 39. Respondents MDP, Smith, and Jones are subject to disciplinary action for
21 unprofessional conduct pursuant to section 4301, subdivision (o), in that Respondents violated or
22 attempted to violate, directly or indirectly, assisted in or abetted the violation of, or conspired to
23 violate provisions or terms of the Pharmacy Law (Bus. & Prof. Code § 4300, et seq.), and federal
24 and state laws governing pharmacy, as follows:

25 a. On and between April 21, 2014 and April 21, 2015, Respondents introduced or
26 delivered for introduction into interstate commerce the drug, domperidone, by compounding and
27 dispensing the drug to patients, as set forth in paragraph 34 above, when, in fact, there was no

28 ///

1 investigational new drug application ("IND") for domperidone approved by the FDA, in violation
2 of 21 U.S.C. section 355, subdivision (a).

3 b. On and between April 21, 2014, and April 21, 2015, Respondents sold, delivered, or
4 gave away the drug domperidone by dispensing the drug to patients, as set forth in paragraph 34
5 above, when, in fact, there was no IND for domperidone approved by the FDA, in violation of
6 Health and Safety Code section 111550.

7 **PETITION TO REVOKE PROBATION**

8 40. This Petition to Revoke Probation is brought before the Board under Probation Term
9 and Condition Number 3 of the Decision and Order in the disciplinary action entitled, "In the
10 Matter of the Accusation Against: Darek Terrell Jones", Case No. 3813. That term and condition
11 states, in pertinent part, that Respondent shall obey all state and federal laws and regulations.

12 41. Respondent's probation is subject to revocation in that Respondent failed to obey all
13 state and federal laws, as set forth in paragraph 26 above.

14 **PRAYER**

15 WHEREFORE, Complainant requests that a hearing be held on the matters alleged in this
16 Accusation and Petition to Revoke Probation, and that following the hearing, the Board of
17 Pharmacy issue a decision:

18 1. Revoking or suspending Pharmacy Permit No. PHY 44342, issued to Medical Dental
19 Pharmacy, Inc., doing business as Medical Dental Pharmacy;

20 2. Revoking or suspending Pharmacist License No. RPH 45423, issued to Diana Lynn
21 Smith, aka Diana Lynn Morton, aka Diana Morton and aka Diana Smith;

22 3. Revoking the probation that was granted by the Board of Pharmacy in Case No. 3813
23 and imposing the disciplinary order that was stayed, thereby revoking Pharmacist License No.
24 RPH 59702 issued to Darek Terrell Jones;


25 4. Revoking or suspending Pharmacist License No. RPH 59702, issued to Darek Terrell
26 Jones;

27 5. Ordering Medical Dental Pharmacy, Inc., doing business as Medical Dental
28 Pharmacy, Diana Lynn Smith, aka Diana Lynn Morton, aka Diana Morton, and Diana Smith, and

1 Darek Terrell Jones to pay the Board of Pharmacy the reasonable costs of the investigation and
2 enforcement of this case, pursuant to Business and Professions Code section 125.3; and

3 6. Taking such other and further action as deemed necessary and proper.

4
5 DATED: 3/18/16



VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

SA2015104552
30157.docx